COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Jaguar Health, Inc. announces exclusive license agreement with GEN for crofelemer products in key territories, including payment of double-digit royalties. Agreement covers FDA-approved indications and potential follow-on uses -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Jaguar Health Provides Update on Nasdaq Listing Status. Company requests appeal hearing after receiving delisting notification. Working on comprehensive analysis of Phase 3 trial for cancer therapy-related diarrhea prevention -
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health announces agreement with FDA on clinical field study design for Canalevia-CA1, a canine-specific treatment for chemotherapy-induced diarrhea in dogs, towards full approval -
COMMUNIQUÉ DE PRESSE
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
Jaguar Health, Inc. donates plant-based drug Mytesi® to Direct Relief, aiding healthcare access. Mytesi® helps HIV/AIDS patients with noninfectious diarrhea. Learn more at https://jaguar.health -
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Jaguar Health announces Orphan Drug Designation application for crofelemer for symptomatic relief and treatment of moderate-to-severe diarrhea caused by bacterial, viral, and parasitic infections, including cholera. Crofelemer is a novel plant-based prescription drug derived from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest
